Immunocore (NASDAQ:IMCR) Reaches New 1-Year Low at $37.83

Immunocore Holdings plc (NASDAQ:IMCR)’s stock price hit a new 52-week low during trading on Monday . The company traded as low as $37.83 and last traded at $38.01, with a volume of 19068 shares traded. The stock had previously closed at $38.46.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on IMCR. Mizuho reduced their target price on shares of Immunocore from $90.00 to $88.00 and set a “buy” rating for the company in a research note on Monday, May 13th. JPMorgan Chase & Co. increased their price objective on Immunocore from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. Leerink Partnrs restated an “outperform” rating on shares of Immunocore in a research note on Monday, April 29th. SVB Leerink started coverage on Immunocore in a research report on Monday, April 29th. They set an “outperform” rating and a $74.00 price target for the company. Finally, Guggenheim reiterated a “buy” rating and issued a $92.00 price objective on shares of Immunocore in a report on Tuesday, April 23rd. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $81.85.

Immunocore Trading Down 2.8 %

The stock has a market cap of $1.80 billion, a price-to-earnings ratio of -29.46 and a beta of 0.84. The business’s 50 day simple moving average is $51.62 and its 200 day simple moving average is $61.34. The company has a quick ratio of 5.94, a current ratio of 5.96 and a debt-to-equity ratio of 1.22.

Immunocore (NASDAQ:IMCR) last issued its earnings results on Wednesday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.12). The firm had revenue of $70.30 million during the quarter, compared to analyst estimates of $70.72 million. Immunocore had a negative net margin of 22.60% and a negative return on equity of 16.54%. The company’s revenue for the quarter was up 27.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.35) earnings per share. On average, research analysts expect that Immunocore Holdings plc will post -1.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IMCR. TD Asset Management Inc raised its position in shares of Immunocore by 14.9% in the fourth quarter. TD Asset Management Inc now owns 346,930 shares of the company’s stock valued at $23,702,000 after purchasing an additional 45,010 shares during the period. Oppenheimer & Co. Inc. acquired a new stake in Immunocore during the fourth quarter worth approximately $1,314,000. Hsbc Holdings PLC acquired a new stake in Immunocore during the fourth quarter worth approximately $4,450,000. Bellevue Group AG boosted its holdings in shares of Immunocore by 4,817.1% during the fourth quarter. Bellevue Group AG now owns 976,054 shares of the company’s stock worth $66,684,000 after acquiring an additional 956,204 shares during the period. Finally, Legato Capital Management LLC grew its position in shares of Immunocore by 61.7% in the fourth quarter. Legato Capital Management LLC now owns 7,235 shares of the company’s stock valued at $494,000 after purchasing an additional 2,762 shares during the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.